cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Pharvaris Nv
5 own
6 watching
Current Price
$19.16
$0.74
(4.02%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
685.25M
52-Week High
52-Week High
33.00000
52-Week Low
52-Week Low
7.93000
Average Volume
Average Volume
0.13M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization685.25M
icon52-Week High33.00000
icon52-Week Low7.93000
iconAverage Volume0.13M
iconDividend Yield--
iconP/E Ratio--
What does the Pharvaris Nv do?
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Read More
News & Events about Pharvaris Nv.
TipRanks Financial Blog
9 months ago
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Paycor HCM (PYCR Research Report), Regeneron (RE... Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Paycor HCM (PYCR Research Report), Regeneron...
Globe Newswire
1 year ago
ZUG, Switzerland, March 18, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced an oral presentation of positive data from its Phase 2 RAPIDe-1 ...
Globe Newswire
1 year ago
ZUG, Switzerland, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced a poster detailing positive data from its Phase 2 RAPIDe-1 study ...
Zolmax
1 year ago
Shares of Pharvaris (NASDAQ:PHVS Get Rating) have earned an average recommendation of Moderate Buy from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has ...
Ticker Report
1 year ago
Pharvaris (NASDAQ:PHVS Get Rating) had its price objective trimmed by SVB Leerink from $20.00 to $18.00 in a report released on Friday, Benzinga reports. The firm currently has an outperform rating on the stock. Separately, JMP Securities increased their target price on Pharvaris from $22.00...
Frequently Asked Questions
Frequently Asked Questions
What is Pharvaris Nv share price today?
plus_minus_icon
Can Indians buy Pharvaris Nv shares?
plus_minus_icon
How can I buy Pharvaris Nv shares from India?
plus_minus_icon
Can Fractional shares of Pharvaris Nv be purchased?
plus_minus_icon
What are the documents required to start investing in Pharvaris Nv stocks?
plus_minus_icon
What is today’s traded volume of Pharvaris Nv?
plus_minus_icon
What is today’s market capitalisation of Pharvaris Nv?
plus_minus_icon
What is the 52-Week High and Low Range of Pharvaris Nv?
plus_minus_icon
What percentage is Pharvaris Nv down from its 52-Week High?
plus_minus_icon
What percentage is Pharvaris Nv up from its 52-Week Low?
plus_minus_icon
Current Price
$19.16
$0.74
(4.02%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00